José Manuel Bartolomé-Nebreda

Author

Also Known As

J. M. Bartolome-Nebreda, J.M. Bartolomé-Nebreda, Jose M. Bartolomé-Nebreda, José M. Bartolomé-Nebreda, José Manuel Bartolomé-Nebreda, José M. Bartolomé-Nebreda

Publications

506

Citations

H-Index

Concepts

All Affiliations

Janssen (Belgium)Universidad de Navarra Vanderbilt University Vanderbilt University Medical Center Instituto de Química Médica

About

José Manuel Bartolomé-Nebreda is an author at Janssen (Belgium) specializing in neuropharmacology, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	308
2	Social Sciences	5	5	167
3	Biochemistry	3	3	78
4	Natural Sciences	1	1	13
5	Chemical Biology	1	1	13

José Manuel Bartolomé-Nebreda

Publications

451

Citations

H-Index

Page 1

	Year	Citations
Biased mGlu 5 -Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents Jerri M. Rook, Zixiu Xiang, Xiaohui Lv, Neuron Signal TransductionMolecular PhysiologyMglu 5Neuromodulation (Medicine)Medicine	2015	128
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature José Manuel Bartolomé-Nebreda, Andrés A. Trabanco, Adriana I. Velter, Expert Opinion on Therapeutic Patents	2021	60
Discovery of VU0409551/JNJ-46778212: An mGlu<sub>5</sub> Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia Susana Conde-Ceide, Carlos M. Martínez‐Viturro, Jesús Alcázar, ACS Medicinal Chemistry Letters Psychotropic MedicationMolecular BiologyPsychopharmacologyPharmacotherapySocial Sciences	2015	52
Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia José Manuel Bartolomé-Nebreda, Francisca Delgado, Maria Luz Martı́n-Martı́n, Journal of Medicinal Chemistry PsychopharmacologyPharmacotherapySocial SciencesMedicinal ChemistryInhibitory Activity	2014	43
Synthesis and Stereochemical Structure−Activity Relationships of 1,3-Dioxoperhydropyrido[1,2-<i>c</i>]pyrimidine Derivatives: Potent and Selective Cholecystokinin-A Receptor Antagonists Mercedes Martín‐Martínez, José Manuel Bartolomé-Nebreda, Isabel Gómez‐Monterrey, Journal of Medicinal Chemistry	1997	37
Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats A. Ahnaou, Xavier Langlois, Thomas Steckler, Psychopharmacology Metabotropic Glutamate ReceptorsPsychiatryNeurophysiologyMedicineNeurotransmitter	2014	30
Dihydrothiazolopyridone Derivatives as a Novel Family of Positive Allosteric Modulators of the Metabotropic Glutamate 5 (mGlu<sub>5</sub>) Receptor José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Francisca Delgado, Journal of Medicinal Chemistry Psychotropic MedicationStructure ActivityPsychopharmacologyVivo Drug MetabolismPharmacotherapy	2013	22
Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders Carlos M. Martínez‐Viturro, Andrés A. Trabanco, Jordi Royes, Journal of Medicinal Chemistry	2020	21
Identification of a Novel Orally Bioavailable Phosphodiesterase 10A (PDE10A) Inhibitor with Efficacy in Animal Models of Schizophrenia. José Manuel Bartolomé-Nebreda, Sergio A. Alonso de Diego, Marta Artola, Journal of Medicinal Chemistry PsychopharmacologyPharmacotherapyPharmaceutical ChemistrySocial SciencesMolecular Pharmacology	2014	20
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-<i>c</i>]pyrimidine-Based Potent and Selective CCK<sub>1</sub> Receptor Antagonists: Structure−Activity Relationship Studies on the Central 1,3-Dioxoperhydropyrido[1,2-<i>c</i>]pyrimidine Scaffold José Manuel Bartolomé-Nebreda, M. Teresa García‐López, Rosario González‐Muñiz, Journal of Medicinal Chemistry	2001	14

Page 1